Yeah, and there is some literature questioning its safety profile. See this disproportionality analysis from a nationwide population-based study of the French

Yeah, and there is some literature questioning its safety profile. See this disproportionality analysis from a nationwide population-based study of the French (full text, figure 2): https://diabetesjournals.org/care/article/46/2/384/147888/GLP-1-Receptor-Agonists-and-the-Risk-of-Thyroid https://diabetesjournals.org/care/article/46/2/384/147888/GL...